Figure 5. TCR multimers block CTL cytotoxicity.
(A) Normal human donor PBMCs were expanded for 3 rounds with capsid peptide or AAV2-empty capsid and pooled for use as effector cells. HLA-matched HHL5-B7 target cells were transduced with AAV2-F9 at 3 × 105 MOI. Effectors and target cells were then plated at an effector/target ratio of 10:1 in the absence or presence of indicated concentrations of TCR multimer. (B and C) In a separate experiment, HHL5-B7 hepatocytes were cultured with either AAV-derived capsid peptides (B) or AAV vectors (C) at the indicated concentrations. The following day, effector cells were added at an effector/target ratio of 10:1 in the absence (open circles) or presence (filled circles) of 20 μg/ml TCR multimer. Effectors were derived from pooled human PBMCs expanded for 1 round with capsid peptide or AAV2-empty capsid.